Cargando…

Talquetamab: A promising immunotherapy for multiple myeloma

Detalles Bibliográficos
Autores principales:	Tariq, Amna, Wahid, Abdul, Asif, Fatima, Khan, Mahnoor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655669/ https://www.ncbi.nlm.nih.gov/pubmed/38023658 http://dx.doi.org/10.1177/20363613231211051

Ejemplares similares

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
por: Narayan, Neha, et al.
Publicado: (2022)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Chari, Ajai, et al.
Publicado: (2023)

PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ye, Jing Christine, et al.
Publicado: (2023)

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
por: Castella, Maria, et al.
Publicado: (2018)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
por: Rasche, Leo, et al.
Publicado: (2023)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma
por: Liu, Yang, et al.
Publicado: (2023)

P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS
por: Oriol, Albert, et al.
Publicado: (2023)

Multiple Myeloma and Alkaline Phosphatase
por: Yavaşoğlu, İrfan, et al.
Publicado: (2015)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Carbamazepine and Multiple Myeloma: Possible Interaction
por: Günaldı, Meral, et al.
Publicado: (2013)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Oligosecretory multiple myeloma: a case report
por: Khurana, Ujjawal, et al.
Publicado: (2016)

DCvax: A promising advancement in oncology for the treatment of glioblastoma
por: Fareed, Areeba, et al.
Publicado: (2023)

Letter to the editor regarding the article “understanding medical professionalism using express team-based learning; a qualitative case-based study”
por: Vafapour, Parmis, et al.
Publicado: (2023)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

Multiple myeloma presenting with focal segmental glomerulosclerosis
por: Valizadeh, Nasim, et al.
Publicado: (2013)

The Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Hangül, Ceren, et al.
Publicado: (2019)

An Unconventional Presentation of Multiple Myeloma: Bazex Syndrome
por: Kandemir Alibakan, Özlem, et al.
Publicado: (2020)

Renal cell carcinoma concomitant with multiple myeloma
por: Narwal, Anubhav, et al.
Publicado: (2022)

Nonsecretory multiple myeloma, how to make a diagnosis?
por: Wiwanitkit, Viroj
Publicado: (2010)

Austrian Syndrome and Multiple Myeloma: A Fatal Combination
por: Baig, Abdur, et al.
Publicado: (2012)

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
por: Ozaki, S, et al.
Publicado: (2015)

Empyema Necessitans: An Unexpected Infectious Presentation of Multiple Myeloma
por: Kapila, Aaysha, et al.
Publicado: (2017)

“A beacon of hope for relapsed multiple myeloma patients: TALVEY™”
por: Khaliq, Nawal, et al.
Publicado: (2023)

Multiple myeloma and fever of unknown origin: a need for therapy
por: Mumoli, N, et al.
Publicado: (2005)

A case of synchronous multiple myeloma and chronic myeloid leukemia
por: Lee, Ji-Young, et al.
Publicado: (2017)

IgA nephropathy in IgG kappa multiple myeloma
por: Couto, Maria Eduarda, et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4gmm97a54jjpopdkk5letojear